Financial Review: Aethlon Medical (AEMD) & Bio-Rad Laboratories, Inc. Class A Common Stock (BIO)
Aethlon Medical (NYSE: BIO) and Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE:BIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.
Insider and Institutional Ownership
7.0% of Aethlon Medical shares are owned by institutional investors. Comparatively, 64.8% of Bio-Rad Laboratories, Inc. Class A Common Stock shares are owned by institutional investors. 6.6% of Aethlon Medical shares are owned by company insiders. Comparatively, 28.0% of Bio-Rad Laboratories, Inc. Class A Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Aethlon Medical and Bio-Rad Laboratories, Inc. Class A Common Stock’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Bio-Rad Laboratories, Inc. Class A Common Stock||44.77%||4.23%||2.99%|
Volatility and Risk
Aethlon Medical has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories, Inc. Class A Common Stock has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.
Earnings & Valuation
This table compares Aethlon Medical and Bio-Rad Laboratories, Inc. Class A Common Stock’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aethlon Medical||$150,000.00||130.53||-$5.67 million||($0.46)||-2.39|
|Bio-Rad Laboratories, Inc. Class A Common Stock||$2.16 billion||4.35||$122.24 million||$4.10||76.91|
Bio-Rad Laboratories, Inc. Class A Common Stock has higher revenue and earnings than Aethlon Medical. Aethlon Medical is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, Inc. Class A Common Stock, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and target prices for Aethlon Medical and Bio-Rad Laboratories, Inc. Class A Common Stock, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Bio-Rad Laboratories, Inc. Class A Common Stock||0||1||4||0||2.80|
Aethlon Medical currently has a consensus target price of $3.00, suggesting a potential upside of 172.73%. Bio-Rad Laboratories, Inc. Class A Common Stock has a consensus target price of $306.25, suggesting a potential downside of 2.88%. Given Aethlon Medical’s stronger consensus rating and higher probable upside, research analysts plainly believe Aethlon Medical is more favorable than Bio-Rad Laboratories, Inc. Class A Common Stock.
Bio-Rad Laboratories, Inc. Class A Common Stock beats Aethlon Medical on 10 of the 14 factors compared between the two stocks.
About Aethlon Medical
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.